Management of NASH: Current and Future Perspectives on Treatment

Fatty Liver Disease: NASH and Related Disorders

Volumn , Issue , 2007, Pages 194-207

  Angulo, Paul ^a   Lindor, Keith D ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Drug therapy; Fibrosis; Hyperglycaemia; Nonalcoholic steatohepatitis (NASH); Pharmacological therapy

Indexed keywords

EID: 30444447803     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987438.ch16     Document Type: Chapter

References (67)

1. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
2. Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001; 120: 1281-5.
3. Teli M, Oliver FW, Burt AD et al. The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-7.
4. Eriksson S, Eriksson KF, Bondesson L. Non-alcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986; 220: 83-8.
5. Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967; 12: 198-208.
6. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N Engl J Med 1970; 282: 829-34.
7. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-13.
8. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol 1991; 12: 224-9.
9. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
10. Vajro P, Fontanella A, Perna C et al. Persistent hyper- aminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-41.
11. Franzese A, Vajro P, Argenziano A et al. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1428-32.
12. Rashid M, Roberts E. Non-alcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48-53.
13. Anonymous. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855-67.
14. Kraus RM, Eckel RH, Howard B et al. AHA dietary guidelines: revision 2000. A statement for health care professionals from the nutrition committee of the American Heart Association. Stroke 2000; 31: 2751-66.
15. Clark MJ Jr, Sterrett JJ, Carson DS. Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin Ther 2000; 22: 899-910; discussion 898.
16. Fernandez MI, Torres MI, Rios A. Steatosis and collagen content in experimental liver cirrhosis are affected by dietary monounsaturated and polyunsaturated fatty acids. Scand J Gastroenterol 1997; 32: 350-6.
17. Assy N, Svalb S, Hussein O. Orlistat (xenical) reverses fatty liver disease and improve hepatic fibrosis in obesepatients with NASH [Abstract]. Hepatology 2001; 34: 251.
18. Harrison SA, Fincke C, Helinski D, Torgerson S. Orlistat treatment in obese, non-alcoholic steatohepatitis patients [Abstract]. Hepatology 2002; 36: 406.
19. Lau G, Chan CL. Massive hepatocellular [correction of hepatocullular] necrosis: was it caused by Orlistat? Med Sci Law 2002; 42: 309-12.
20. Campbell JM, Hung TK, Karam JH, Forsham PH. Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med 1977; 137: 602-10.
21. Ackerman NB. Protein supplementation in the management of degenerating liver function after jejunoileal bypass. Surg Gynecol Obstetr 1979; 149: 8-14.
22. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass: prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982; 82: 535-48.
23. Weiner R, Blanco-Engert R, Weiner S et al. Outcome after laparoscopic adjustable gastric banding: 8 years' experience. Obes Surg 2003; 13: 427-34.
24. Buchman AL, Dubin M, Jenden D et al. Lecithin increases plasma free choline and decreases hepatic steatosis in longterm total parenteral nutrition in rats. Gastroenterology 1992; 102: 1363-70.
25. Buchman AL, Dubin MD, Moukarzel AA et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995; 22: 1390-403.
26. Pappo I, Becovier H, Berry EM, Freud HR. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat. J Surg Res 1991; 51: 106-12.
27. Freud HR, Muggia-Sullan M, Lafrance R et al. A possible beneficial effect of metronidazole in reducing TPN- associated liver function derangements. J Surg Res 1985; 38: 356-63.
28. Lin HZ, Yang SQ, Chuckaree C et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003.
29. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22: 185-94.
30. Caldwell SH, Hespenheiden EE, Redick JA et al. A pilot study of thiazolidinedione, troglitazone, in non-alcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.
31. Chitturi S, George J. Hepatotoxicity of commonly used drugs: non-steroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsivants, lipidlowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-83.
32. Neuschwander-Tetri BA, Sponseller C, Hamptom KK et al. Rosiglitazone improves insulin sensitivity, ALT and hepatic steatosis in patients with non-alcoholic steatohep- atitis [Abstract]. Gastroenterology 2002; 122 (Suppl.): 622.
33. Neuschwander-Tetri BA, Brunt EM, Bacon BR et al. Histological improvement in NASH following reduction of insulin resistance with 48-week treatment with the PPAPy agonist rosiglitazone [Abstract]. Hepatology 2002; 36: 379.
34. Acosta RC, Molina EG, O'Brien CB et al. The use of pioglitazone in non-alcoholic steatohepatitis [Abstract]. Gastroenterology 2001; 120 (Suppl.): 2778.
35. Sanyal AJ, Contos MJ, Sargeant C et al. A randomized controlled pilot study or pioglitazone and vitamin E versus vitamin E for non-alcoholic steatohepatitis [Abstract]. Hepatology 2002; 36: 382.
36. Pomrat K, Lutchman G, Kleiner DE et al. Pilot study of pioglitazone in non-alcoholic steatohepatitis [Abstract]. Gastroenterology 2003; 124 (Suppl 1.): 708.
37. Marchesini G, Brizi M, Bianchi G et al. Metformin in nonalcoholic steatohepatitis. Lancet 2001; 358: 893-4.
38. Nair S, Diehl AM, Perrillo R. Metformin in non-alcoholic steatohepatitis (NASH): efficacy and safety a preliminary report [Abstract]. Gastroenterology 2002; 122 (Suppl.): 4.
39. Lavine JE. Vitamin E treatment of non-alcoholic steato- hepatitis in children: a pilot study. J Pediatr 2000; 136: 734-8.
40. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-β1 level and efficacy of a-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72.
41. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-90.
42. Abdelmalek M, Angulo P, Jorgensen RA, Sylvestre P, Lindor KD. Betaine, a promising new agent for patients with non-alcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711-7.
43. Miglio F, Rovati LC, Santoro A, Setkikar I. Efficacy and safety of oral betaine glucurontae in non-alcoholic steatohepatitis. Arzneimittelforschung/Drug Res 2000; 50 (II): 722-7.
44. Gulbahar O, Karasu ZA, Ersoz G, Akarca US, Musoglu A. Treatment of non-alcoholic steatohepatitis with N- acetylcysteine [Abstract]. Gastroenterology 2000; 118 (Part 2 Suppl.): 6550.
45. Desai TK. Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis [Abstract]. Gastroenterology 2000; 118 (Part 1, Suppl. 2): 1071.
46. Nitecki J, Jackson FW, Allen ML, Farr VL, Jackson FW. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) [Abstract]. Gastroenterology 2000; 118 (Part 2, Suppl. 2): 6679.
47. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of non-alcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9.
48. Rawat AK. Effect of clofibrate on cholesterol and lipid metabolism in ethanol-treated mice. Res Commun Chem Pathol Pharmacol 1975; 10: 501-10.
49. Laurin J, Lindor KD, Crippin JS et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.
50. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384.
51. Horlander JC, Kwo PY, Cummings OW, Koukoulis G. Atorvastatin for the treatment of NASH [Abstract]. Gastroenterology 2001; 120 (Suppl.): 2767.
52. Merat S, Malekzadeh R, Sohrabi MR et al. Probucol in the treatment of non-alcoholic steatohepatitis: a doubleblind randomized controlled study. J Hepatol 2003; 38: 414-8.
53. Guma C, Viola L, Thome M, Galdame O, Alvarez E. Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: results of a prospective clinical controlled trial [Abstract]. Hepatology 1997; 26 (Part 2 Suppl.): 1036.
54. Ceriani R, Bunati S, Morini L, Sacchi E, Colombo G. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [Abstract]. Hepatology 1998; 28 (Part 2 Suppl.): 894.
55. Holoman J, Glasa J, Kasar J et al. Serum markers of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH): correlation to liver morphology and effect of therapy [Abstract]. J Hepatol 2000; 32 (Suppl 2): 210.
56. Letterson P, Fromenty B, Terris B, Degott C, Passayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-8.
57. Yang SS, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-62.
58. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
59. Loguercio C, De Simone T, Federico A et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol 2002; 97: 2144-6.
60. Cortez-Pinto H, Chatham J, Chacko VP et al. Alterations in liver ATP homeostasis in human non-alcoholic steato- heaptitis: a pilot study. J Am Med Assoc 1999; 282: 1659-64.
61. Weltman MD, Farrell GC, Liddle C. Increased hepato- cyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
62. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
63. Leclercq IA, Farrell GC, Field J et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75.
64. Friedman SL. Molecular regulation of hepatic fibrosis: an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50.
65. Bataller R, Brenner DA. Stellate cells as a target for treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-52.
66. Talwalkar J, Keach J, Angulo P, Lindor KD. Health- related quality of life assessment in non-alcoholic steato- hepatitis [Abstract]. Hepatology 2001; 34 (Suppl): 309.
67. Talwalkar AJ, Donlinger JJ, Gossard AA, Lindor KD. Health state preferences among patients with non-alcoholic steatohepatitis [Abstract]. Hepatology 2002; 36 (Suppl): 382.